Last $93.85 USD
Change Today +0.58 / 0.62%
Volume 6.1M
CELG On Other Exchanges
Symbol
Exchange
NASDAQ GS
Mexico
Frankfurt
NASDAQ GM
As of 8:10 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

86 Morris Avenue

Summit, NJ 07901

United States

Phone: 908-673-9000

Fax: 908-673-9001

its first approvals from the U.S. Food and Drug Administration (FDA) and the European Commission (EC) during 2013 for multiple myeloma for patients who have received at least two prior therapies, including lenalidomide and bortezomib in the United States and the European Union. POMALYST/IMNOVID is also being evaluated in multiple trials in various phases for expanded usage in multiple myeloma and in a phase II trial for systemic sclerosis. POMALYST is distributed in the United States through contracted pharmacies under the POMALYST REMS program, which is a proprietary risk-management distribution program tailored specifically to provide for the safe and appropriate distribution and use of POMALYST. Internationally, POMALYST/IMNOVID is distributed under mandatory risk-management distribution programs tailored to meet local authorities' specifications to provide for the safe and appropriate distribution and use of POMALYST/IMNOVID. THALOMID (thalidomide): In combination with dexamethasone, THALOMID® is marketed in the United States for patients with newly diagnosed multiple myeloma and for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) an inflammatory complication of leprosy and as maintenance therapy for prevention and suppression of the cutaneous manifestation of ENL recurrence. Thalidomide CelgeneTM in combination with melphalan and prednisone is marketed in the European Union as a first line treatment for patients with untreated multiple myeloma who are aged sixty-five years of age or older or ineligible for high dose chemotherapy. THALOMID is distributed in the United States under the company’s THALOMID REMS program, which is a proprietary risk-management distribution program tailored specifically to provide for the safe and appropriate distribution and use of THALOMID. Internationally, THALOMID and Thalidomide Celgene are also distributed under mandatory risk-management distribution programs tailored to meet local authorities' specifications to provide for the safe and appropriate distribution and use of THALOMID and Thalidomide Celgene. ISTODAX (romidepsin): ISTODAX is approved in the United States for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy and for the treatment of PTCL in patients who have received at least one prior therapy. ISTODAX has received orphan drug designation for the treatment of non-Hodgkin’s T-cell lymphomas, including CTCL and PTCL. Azacitidine for injection (generic version of VIDAZA): The company contracted with Sandoz AG to sell azacitidine for injection, which it supplies. FOCALIN, FOCALIN XR, and RITALIN LA: The company licensed the worldwide rights (excluding Canada) regarding certain chirally pure forms of methylphenidate for FOCALIN and FOCALIN XR to Novartis. It also licensed to Novartis the rights related to long-acting formulations of methylphenidate and dex-methylphenidate products, which are used in FOCALIN XR and RITALIN LA. Preclinical and Clinical Stage Pipeline Oral Anti-inflammatory Agents: The company is developing novel, orally administered small molecules that specifically target PDE4, an intracellular enzyme that modulates the production of multiple pro-inflammatory and anti-inflammatory mediators, including interleukin-2 (IL-2), IL-10, IL-12, IL-23, INF-gamma, TNF-α, leukotrienes and nitric oxide synthase. OTEZLA (apremilast), the company’s lead product candidate in inflammation and immunology, has demonstrated statistically significant and clinically meaningful benefits in recent phase III trials in the treatment of psoriasis (ESTEEM 1 and 2 trials), previously treated psoriatic arthritis (PALACE 1, 2 and 3 trials) and psoriatic arthritis in treatment-naïve patients (PALACE 4 trial). OTEZLA (apremilast) is also being evaluated in a phase III trial for ankylosing spondylitis and a phase II trial for Behçet's disease has been completed. Next Generation of Thalidomide Analogues: CC-122 and CC-220 represent novel compounds that are in phase I clinical trials for hematological and solid tumor cancers. Cellular Ther

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CELG:US $93.85 USD +0.58

CELG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biogen Idec Inc $329.24 USD -0.75
Bristol-Myers Squibb Co $51.51 USD +0.39
Eli Lilly & Co $66.53 USD -0.06
Shire PLC 5,290 GBp -30.00
Thermo Fisher Scientific Inc $123.24 USD -0.89
View Industry Companies
 

Industry Analysis

CELG

Industry Average

Valuation CELG Industry Range
Price/Earnings 54.1x
Price/Sales 10.6x
Price/Book 13.1x
Price/Cash Flow 43.2x
TEV/Sales 8.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELGENE CORP, please visit www.celgene.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.